A Phase Ib Clinical Trial of TQB2928 Injection Combined With Penpulimab in the Treatment of Patients With Advanced Malignant Tumors.
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Penpulimab (Primary) ; TQB 2928 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 04 Aug 2024 According to ClinicalTrials.gov record, trial was terminated Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit
- 04 Aug 2024 Status changed from recruiting to discontinued.
- 28 May 2024 Status changed from not yet recruiting to recruiting.